Home / Peptide Monographs / Pinealon

Pinealon: what the human research actually shows

Why I looked into this

Pinealon keeps showing up in longevity and nootropic corners of the internet as a cognitive bioregulator, usually in the same sentence as Epitalon and usually described as if it has a clinical record. When I went to read the primary literature, I found a consistent pattern: plenty of in-vitro and rodent work from the Khavinson group, a handful of Russian-language gray-literature mentions of human use, and zero published human trials in any PubMed-indexed journal.

That pattern is itself the story. A compound does not have to be scam-adjacent to sit on a thin evidence base, and the Russian bioregulator program produces real preclinical papers. But readers deserve to know where the record ends.

What Pinealon actually is

Pinealon is a synthetic tripeptide made of three amino acids: glutamate, aspartate, and arginine. Its laboratory code is EDR. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, the same group behind Epitalon, Cartalax, and a broader family of compounds the lab labels “peptide bioregulators.”

The bioregulator framing positions these short peptides as signaling fragments derived from or inspired by endogenous tissue peptides, with proposed activity in the nervous system and in aging biology. In Russia, Pinealon is sold as a dietary supplement for cognitive and anti-aging use, not as a drug. It has never been submitted for FDA review and has never been the subject of a registered clinical trial in the US or EU.

What the human research shows

Known safety signals in humans

There is no published human safety dataset for Pinealon that I could locate. No Phase 1 tolerability study, no pharmacokinetic paper in humans, no independent pharmacovigilance file. Russian supplement marketing generally describes the product as well tolerated, but that claim is not backed by the kind of formal surveillance the word would imply in a Western regulatory context.

Long-term safety in humans, interactions with common medications, reproductive effects, and any effect in young healthy adults are all unknown in the published record. Post-market adverse event reports are near-zero, which is the expected pattern for a compound sold as a supplement in one country with no Western regulatory surveillance. Absence of reports is not evidence of safety.

FDA and legal status in the US

Pinealon sits entirely outside the US regulated drug pipeline. It is not on the 503A bulk drug substances list, it is not part of the July 2026 PCAC review, and there is no registered Western clinical trial that would move it toward consideration. The regulatory status is effectively the same today as it was in 2010: a Russian supplement with no US pathway.

That matters for one reason in particular. When a compound has no FDA approval, no 503A status, and no active regulatory review, there is no institutional check on label accuracy, identity, or purity in the US market. Whatever regulatory oversight exists happens in Russia, under a supplement framework, on a product made for a different consumer market.

How to evaluate a source: the safety framework

Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.

The wrinkle for Pinealon specifically

The specific source-safety problem with Pinealon is twofold. First, what gets sold as “Pinealon” in the US research-chemical market is almost never the Russian retail supplement product. It is synthesized material with no US pharmacopoeia monograph, no independent identity-testing standard, and no enforcement of what the label actually contains. A short tripeptide is also relatively easy to substitute with a cheaper or unrelated sequence in a way that casual buyers cannot detect.

Second, the Russian retail product that inspired the compound is a dietary supplement under a regulatory regime that does not resemble the FDA or FTC framework US readers assume. Importing it does not transfer that regulatory context. You are buying a product that has been made and labeled for a different country’s rules, and that’s the best case. The worst case is research-chemical material that is labeled “Pinealon” and chemically contains something else.

Cost reality

Expect a wide price range for material labeled “Pinealon” from research-use-only suppliers, generally falling between inexpensive short-peptide territory and the prices you see for better-characterized compounds. A licensed 503A compounding pharmacy would almost certainly decline to compound it, because the compound is not on the bulk drug substances list and has no US clinical record.

Cost is a poor quality signal for Pinealon specifically, because the cheap end of the market is the most likely place to see identity substitution, and the expensive end is not paying for independent testing you can verify. Either way, what you cannot buy here is a chain of custody that resembles a prescription medication.

Questions worth asking any source

• Can you provide a certificate of analysis from a third-party lab, not in-house testing, confirming the tripeptide sequence Glu-Asp-Arg?
• Are you a licensed 503A compounding pharmacy with a verifiable US state license, or a research-chemical supplier?
• Do you require a valid prescription from a licensed clinician?
• Do you have a physical US address and a phone number I can verify by calling?
• What is your process when a batch fails identity or purity testing? Who audits it?

My honest take

Questions to ask your doctor

If you are considering Pinealon, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.

1. I have been reading about Pinealon and the broader Russian bioregulator program. Are you familiar with any of it, and do you see a clinical reason a compound like this would be worth discussing in my specific situation?
2. Given that there is no published human clinical trial of Pinealon, how would you weigh that absence in your clinical judgment?
3. If I were curious about cognitive or anti-aging interventions, what FDA-approved or better-evidenced options would you want to rule in or out first?
4. What baseline labs would you want to see before any novel peptide use, and what would you re-check later?
5. If I developed unusual symptoms while using a novel peptide (headache, mood change, sleep pattern disruption, hormonal shifts), what should I do and who should I contact first?
6. Is there a conventional option that addresses whatever outcome I am hoping a bioregulator peptide would produce, that we should try or rule out first?

What to do next

Sources

• Khavinson VKh, Tarnovskaya SI, Linkova NS, Pronyaeva VE, Shataeva LK, Yakutseni PP. “Short cell-penetrating peptides: a model of interactions with gene promoter sites.” Bulletin of Experimental Biology and Medicine. 2013;154(3):403-410. PMID 23484211. Preclinical modeling work from the Khavinson group.
• Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V. “Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.” International Journal of Clinical and Experimental Medicine. 2012;5(2):179-185. PMID 22567179. Rodent study.
• Khavinson VKh, Lin’kova NS, Kvetnoi IM, Kvetnaia TV, Polyakova VO, Korf HW. “Molecular cellular mechanisms of peptide regulation of melatonin synthesis in pinealocyte culture.” Bulletin of Experimental Biology and Medicine. 2012;153(2):255-258. PMID 22808434. In-vitro cell culture work.
• ClinicalTrials.gov and WHO International Clinical Trials Registry Platform searches for “Pinealon” and the EDR tripeptide sequence, conducted April 2026. No registered or completed human clinical trial returned.

I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.

Related monographs